| abstract |
COMBINATION THERAPY FOR COPD The invention concerns an aerosol formulation suitable for 5 administering to COPD patients by means of a pressurized metered dose inhaler (pMDI), comprising glycopyrronium bromide in combination with formoterol. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the 10 formulation further comprises beclometasone dipropionate. |